Form 4: MAIA CEO Vlad Vitoc Boosts Stake with Share Purchase

MAIA Biotechnology's CEO, Vlad Vitoc, increased his direct ownership by acquiring 10,500 shares of common stock at an average price of $0.9661.

Summary

• Vlad Vitoc, Chief Executive Officer, Director, and 10% Owner of MAIA Biotechnology, Inc., acquired 10,500 shares of common stock.
• The shares were purchased on November 25, 2025, at a weighted average price of $0.9661 per share, with prices ranging from $0.9606 to $0.9745.
• Following this transaction, Mr. Vitoc directly beneficially owns 831,421 shares of common stock.
• Additionally, 210,000 shares are indirectly beneficially owned by Mr. Vitoc's spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The purchase of shares by the CEO, a director, and a 10% owner, signals strong insider confidence in the company's prospects, which is a positive indicator for investors. The transaction being part of a 10b5-1 plan suggests a pre-planned acquisition rather than an opportunistic one, but still reflects a commitment to increasing ownership.

Positives

• The Chief Executive Officer, a Director, and a 10% owner, increased his direct stake in the company by purchasing 10,500 shares.
• Insider buying can signal management's confidence in the company's future prospects and valuation.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
• The reporting person disclaims beneficial ownership of these shares [held by spouse] except to the extent of his pecuniary interest therein.

Industry Context

Insider purchases, especially by high-ranking executives like the CEO, are often viewed positively by the market as they can indicate management's belief in the company's undervaluation or strong future prospects, which is a common sentiment indicator across various industries, including biotechnology.

Comparison to Industry Standards

• This filing is a standard insider transaction report (Form 4) and does not provide specific operational or financial results that can be directly compared to industry benchmarks or competitor performance. Insider buying activity itself is a common occurrence across publicly traded companies, and the significance of this particular transaction would be assessed in the context of MAIA's overall market capitalization, trading volume, and the executive's total compensation and holdings.

Corporate Governance

Related Party Transactions

• 210,000 shares are indirectly beneficially owned by Mr. Vitoc's spouse, for which the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: May view the CEO's share purchase as a positive signal of confidence, potentially leading to increased investor interest and a positive impact on share price.
• Employees: No direct impact mentioned, but a confident management team can foster a more stable work environment.

Key Dates

Recommendation

The CEO's decision to increase his personal stake in MAIA Biotechnology, especially as a 10% owner and director, is a strong vote of confidence in the company's future. While this transaction was made under a 10b5-1 plan, indicating it was pre-scheduled, the underlying decision to acquire more shares at this price point suggests management believes the stock is undervalued or has significant upside potential. This insider buying activity, particularly from a key executive, often precedes positive developments or reflects a belief in the company's strategic direction and operational execution. For a seasoned investor, this signals a potential 'buy' opportunity, aligning with management's conviction.

Keywords

MAIA Biotechnology, MAIA, Vlad Vitoc, Insider Buying, Form 4, CEO, Director, Share Purchase, Biotechnology, Equity Acquisition